UDCA AMP; METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 原发性胆汁性肝硬变(PBC)是一种原因不明的疾病，肝脏中的小胆管因炎症而缓慢破坏。大多数医生认为，PBC是由于针对肝脏胆管的异常免疫反应所致。它被认为是一种自身免疫性疾病。胆管丢失会导致胆汁回流到肝脏，最终导致肝损伤、肝硬变和可能的肝功能衰竭。 目前尚无针对PBC的特效治疗方法。UDCA和甲氨蝶呤可能在治疗这种自身免疫性疾病方面有用。这项研究将检验联合应用UDCA和甲氨蝶呤是否比单独使用UDCA更好。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary biliary cirrhosis (PBC) is a disease of unknown cause in which the small bile ducts in the liver are destroyed slowly by inflammation. Most physicians believe that PBC is due to an abnormal immune response directed against the bile ducts in the liver. It is considered to be an autoimmune disease. Loss of bile ducts causes bile to back up in the liver and ultimately leads to liver damage, liver cirrhosis and possibly liver failure. There is no known specific treatment for PBC at present. UDCA and methotrexate may be useful in the treatment of this autoimmune disease. This study will examine whether treatment with UDCA and methotrexate is better than treatment with UDCA alone.